The sustained effects of aripiprazole-augmented clozapine treatment on the psychotic symptoms and metabolic profiles of patients with refractory schizophrenia

Journal of Clinical Psychopharmacology

Volumn 32, Issue 2, 2012, Pages 282-284

  Chang, Jae Seung ^a   Lee, Nam Young ^b   Ahn, Yong Min ^b   Kim, Yong Sik ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHOLESTEROL; CLOZAPINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROLACTIN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADVERSE DRUG REACTION; BRIEF PSYCHIATRIC RATING SCALE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INNER TENSION; LETTER; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCHEDULE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS; SCHIZOPHRENIA; SIDE EFFECT; SLEEP DISORDER; WEIGHT REDUCTION; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; HUMANS; SCHIZOPHRENIA;

EID: 84863259159     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182485871     Document Type: Letter

References (15)

1. Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res. 2011;127:93-99.
2. Li Z, Ichikawa J, Dai J, et al. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol. 2004;493:75-83. (Pubitemid 38746934)
3. Ziegenbein M, Wittmann G, Kropp S. Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation. Clin Drug Investig. 2006;26:117-124.
4. Barbui C, Signoretti A, Mule S, et al. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull. 2009;35:458-468.
5. Paton C, Whittington C, Barnes TR. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol. 2007;27:198-204. (Pubitemid 46594939)
6. Taylor DM, Smith L. Augmentation of clozapine with a second antipsychoticVa meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand. 2009;119:419-425.
7. Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35:443-457.
8. Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69:720-731. (Pubitemid 351838681)
9. Fleischhacker WW, Heikkinen ME, Olie JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2010;13: 1115-1125.
10. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry. 2010;23:103-111.
11. Glick ID, Poyurovsky M, Ivanova O, et al. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients. J Clin Psychiatry. 2008;69:1856-1859.
12. Englisch S, Esslinger C, Inta D, et al. Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole. Clin Neuropharmacol. 2009;32:227-229.
13. Schirmbeck F, Esslinger C, Rausch F, et al. Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. Psychol Med. 2011;41:2361-2373.
14. Egashira N, Okuno R, Matsushita M, et al. Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT) 1A receptorYindependent mechanisms. Eur J Pharmacol. 2008;592:103-108.
15. Englisch S, Weinbrenner A, Inta D, et al. Aripiprazole for the management of olanzapine-induced weight gain. Pharmacopsychiatry. 2009;42:166-167.